*2.2.1.3 Preliminary results presented at the CTOS meeting, November, 2020*

Overall, INBRX-109 was well tolerated and approximately 90% of patients showed no signs of hepatotoxicity. The pharmacokinetics of INBRX-109 were approximately dose proportional across all doses tested and thus support dosing every 3 weeks without administration of any premedications. All patients have thus far tested negative for anti-drug antibodies. Maximum tolerated dose was not reached in the dose escalation cohort and only one dose-limiting toxicity was experienced. Very few serious adverse events that occurred were attributable to the drug being studied. One patient with mesothelioma has been reported to have experienced acute hepatic failure leading to death that could possibly be related to the study drug. Evidence of anti-cancer effects were observed in patients with chondrosarcoma, resulting in durable partial responses and stable disease.
